SHAREHOLDERS AGREEMENTShareholders Agreement • April 3rd, 2024 • Inventiva S.A. • Pharmaceutical preparations
Catalys Pacific Fund II, LP (“Catalys”), Inventiva S.A. (“Inventiva”) and Hepalys Pharma, Inc. (the “Company”) enter into this Shareholders Agreement (this “Agreement”) on September 20th, 2023 in respect of the Company on the terms and conditions set forth below.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 3rd, 2024 • Inventiva S.A. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of September 20th, 2023 (the “Effective Date”), by and between INVENTIVA S.A., a company incorporated under the laws of France, having its principal place of business at 50, rue de Dijon à Daix (21121), France (“Inventiva”), and Hepalys Pharma, Inc., a company incorporated under the laws of Japan, having its registered office located at 2-3-11, Nihonbashihoncho, Chuo-ku, Tokyo 103-0023 (“Licensee”).
